<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00392067</url>
  </required_header>
  <id_info>
    <org_study_id>LEO19123-C21</org_study_id>
    <nct_id>NCT00392067</nct_id>
  </id_info>
  <brief_title>LEO19123 Cream in the Treatment of Atopic Dermatitis</brief_title>
  <official_title>LEO19123 Cream in the Treatment of Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <brief_summary>
    <textblock>
      To compare the efficacy and safety of two different dose combinations of LEO19123
      (calcipotriol and LEO80122) with LEO19123 cream vehicle for 3 weeks in the treatment of
      patients with atopic dermatitis
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proof of concept</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Atopic Dermatitis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcipotriol and LEO80122 (LEO19123 cream)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of atopic dermatitis according to Hanifin and Rajka

          -  The score of erythema, induration/papulation, excoriation and lichenification, four of
             the five clinical signs in the Total Severity Score, should at least correspond to
             moderate involvement, i.e. severity greater than or equal to 2, at Visit 1

          -  Treatment area amenable to topical treatment

          -  Attending a hospital outpatient clinic or the private practice of a dermatologist

          -  Following verbal and written information about the trial, the patient must provide
             signed and dated informed consent before any study related activity is carried out,
             including activities relating to washout period

          -  Males between 18-50 years

        Exclusion Criteria:

          -  Systemic treatment with immunosuppressive drugs (e.g. methotrexate, cyclosporine,
             azathioprine) or corticosteroids within 4 weeks prior to randomisation. (Inhaled or
             intranasal steroids for asthma or rhinitis may be used)

          -  PUVA or UVB therapy within 4 weeks prior to randomisation

          -  Topical treatment with immunomodulators (pimecrolimus, tacrolimus) or corticosteroids
             from WHO groups III or IV within 2 weeks prior to randomisation

          -  Other topical therapy on the treatment area (except for the use of emollient on the
             entire body and use of hydrocortisone cream 1% on AD lesions on head and neck) within
             1 week prior to randomisation

          -  Use of any other kind of treatment (drug, non-drug) for AD during the study except for
             the use of: - Investigational product on trunk and limbs lesions only during the
             treatment phase - Hydrocortisone cream 1% on head and neck lesions - Emollient on the
             entire body

          -  Use of anti-histamines during the study

          -  Current diagnosis of exfoliative erythrodermia

          -  Clinical infection (impetiginised atopic dermatitis) on the treatment area

          -  Planned exposure to amount of sun or ultraviolet light during the study that may
             affect atopic dermatitis

          -  Known or suspected hypersensitivity to component(s) of the investigational product

          -  Known or suspected severe renal insufficiency or severe hepatic disorders

          -  Patients with history/signs/symptoms suggestive of an abnormality of calcium
             homeostasis associated with clinically significant hypercalcaemia

          -  Patients with history of cancer including skin cancer

          -  Patients with history of an immunocompromised disease (e.g. lymphoma, HIV,
             Wiskott-Aldrich Syndrome)

          -  Current participation in any other interventional clinical trial

          -  Patients who have received treatment with any non-marketed drug substance (i.e. an
             agent which has not yet been made available for clinical use following registration)
             within 4 weeks prior to randomisation

          -  Previously randomised in this study

          -  Patients known or suspected of not being able to comply with a trial protocol (e.g.
             alcoholism, drug dependency, or psychotic state)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristian Thestrup-Pedersen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hudklinikken</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinique Dermatologique Maizerets</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1J 1X7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hudklinikken</name>
      <address>
        <city>Nyk√∏bing F</city>
        <zip>4800</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00250</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manchester Royal Infirmary</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2006</study_first_submitted>
  <study_first_submitted_qc>October 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2006</study_first_posted>
  <last_update_submitted>April 29, 2008</last_update_submitted>
  <last_update_submitted_qc>April 29, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2008</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcipotriene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

